Company intelligence / Profile preview

Aummune

Tel Aviv-Yafo, Tel Aviv, Israelaummune.com ↗

Ownership: Private
Employees: ~17
Development stage: Phase 1

Overview

Aummune has completed a Phase 1 trial of its lead candidate AM003, which met its primary endpoint of safety and tolerability. The study enrolled 12 patients with various solid tumors. No dose-limiting toxicities were observed, and most adverse events were mild to moderate and clinically manageable. Initial signs of clinical activity showed 3 out of 11 evaluable patients (27%) achieved stable disease, and 3 out of 13 injected lesions (23%) showed a decrease in size of ≥40%.

Therapeutic areas: Oncology
Modalities: Oligonucleotide-based therapiesAptamersImmunotherapy
Industry: Biotech

Drug pipeline

1 asset

AM003

Beyond the preview

Go deeper on Aummune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aummune.

Explore the full profile